Why Is SoundHound AI Stock Up So Much?
Like many companies improving AI technologies and exploring ways to…
Sell
46
AMGN Quote, Financials, Valuation and Earnings
Last price:
$264.26
Seasonality move
:
6.39%
Day range:
$261.36 - $264.55
52-week range:
$253.30 - $346.85
Dividend yield:
3.4%
P/E ratio:
33.87x
P/S ratio:
4.38x
P/B ratio:
18.89x
Volume:
1.5M
Avg. volume:
4.7M
1-year change:
-6.92%
Market cap:
$142.2B
Revenue:
$28.2B
EPS (TTM):
$7.81
Analysts' Opinion
-
Consensus RatingAmgen has received a consensus rating of Hold. The company's average rating is a Hold based on 10 Buy ratings, 15 Hold ratings, and 2 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $322.43, Amgen has an estimated upside of 21.91% from its current price of $264.49.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $195.00 representing 100% downside risk from its current price of $264.49.
Fair Value
-
According to the consensus of 27 analysts, Amgen has 21.91% upside to fair value with a price target of $322.43 per share.
AMGN vs. S&P 500
-
Over the past 5 trading days, Amgen has underperformed the S&P 500 by -3.4% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Amgen does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Amgen has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Amgen reported revenues of $8.5B.
Earnings Growth
-
Amgen has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Amgen reported earnings per share of $5.22.
Enterprise value:
193.6B
EV / Invested capital:
2.85x
Price / LTM sales:
4.38x
EV / EBIT:
24.48x
EV / Revenue:
5.95x
PEG ratio (5yr expected):
--
EV / Free cash flow:
30.81x
Price / Operating cash flow:
22.70x
Enterprise value / EBITDA:
14.36x
Gross Profit (TTM):
$19.7B
Return On Assets:
4.57%
Net Income Margin (TTM):
13%
Return On Equity:
65.35%
Return On Invested Capital:
6.14%
Operating Margin:
24.07%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $26.3B | $26.8B | $32.5B | $6.9B | $8.5B | |
| Gross Profit | $20B | $19.7B | $19.7B | $5.1B | $5.2B | |
| Operating Income | $9.6B | $8.9B | $6.2B | $2B | $2B | |
| EBITDA | $12.4B | $14.8B | $13.5B | $3.6B | $5.3B | |
| Diluted EPS | $12.47 | $14.07 | $7.81 | $3.22 | $5.22 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $22.7B | $24.4B | $24.1B | $48.5B | $26.8B | |
| Total Assets | $64.6B | $65B | $63.7B | $90.5B | $90.9B | |
| Current Liabilities | $10B | $14.8B | $14.3B | $17B | $20.3B | |
| Total Liabilities | $53.7B | $56.8B | $60B | $82.9B | $83.4B | |
| Total Equity | $11B | $8.2B | $3.7B | $7.7B | $7.5B | |
| Total Debt | $34.3B | $37.6B | $38.7B | $60.5B | $60.4B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $9.9B | $10.6B | $7.3B | $2.8B | $3.6B | |
| Cash From Investing | -$2.8B | -$2.6B | -$27.7B | -$262M | -$210M | |
| Cash From Financing | -$9.5B | $17.2B | -$5.3B | -$2B | -$3.7B | |
| Free Cash Flow | $9B | $9.4B | $6.3B | $2.5B | $3.3B | |
AMGN
Sector
Market Cap
$142.2B
$46.1M
Price % of 52-Week High
76.26%
46.02%
Dividend Yield
3.4%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-6.92%
-30.52%
Beta (5-Year)
0.547
0.772
Dividend yield:
3.4%
Annualized payout:
$8.52
Payout ratio:
112.7%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$264.36
200-day SMA
Sell
Level
$304.68
Bollinger Bands (100)
Sell
Level
287.85 - 332.97
Chaikin Money Flow
Buy
Level
141.9M
20-day SMA
Sell
Level
$272.02
Relative Strength Index (RSI14)
Sell
Level
33.07
ADX Line
Buy
Level
8.39
Williams %R
Neutral
Level
-58.0899
50-day SMA
Sell
Level
$294.75
MACD (12, 26)
Sell
Level
-9.03
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Neutral
Level
143.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.4371)
Sell
CA Score
(Annual)
Level (-1.7488)
Buy
Beneish M-Score
(Annual)
Level (-2.2478)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (0.8599)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Stock Forecast FAQ
In the current month, AMGN has received 10 Buy ratings 15 Hold ratings, and 2 Sell ratings. The AMGN average analyst price target in the past 3 months is $322.43.
-
Where Will Amgen Stock Be In 1 Year?
According to analysts, the consensus estimate is that Amgen share price will rise to $322.43 per share over the next 12 months.
-
What Do Analysts Say About Amgen?
Analysts are divided on their view about Amgen share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Amgen is a Sell and believe this share price will drop from its current level to $195.00.
-
What Is Amgen's Price Target?
The price target for Amgen over the next 1-year time period is forecast to be $322.43 according to 27 Wall Street analysts, 10 of them rate the stock a Buy, 2 rate the stock a Sell, and 15 analysts rate the stock a Hold.
-
Is AMGN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Amgen is a Hold. 15 of 27 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of AMGN?
You can purchase shares of Amgen via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Amgen shares.
-
What Is The Amgen Share Price Today?
Amgen was last trading at $264.26 per share. This represents the most recent stock quote for Amgen. Yesterday, Amgen closed at $264.49 per share.
-
How To Buy Amgen Stock Online?
In order to purchase Amgen stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
